Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood
暂无分享,去创建一个
D. Brenner | T. Angel | Shanshan Liu | S. Turner | M. Hellerstein | R. Loomba | Edna Nyangau | Kelvin W. Li | C. Emson | M. Decaris | J. Cui | C. Beysen | M. Colangelo | Michelle Gatmaitan | C. Hernandez | Yenny Wang | L. Lazaro | Thomas Angel
[1] Lynne Pearce,et al. Non-alcoholic fatty liver disease. , 2016, Nursing standard (Royal College of Nursing (Great Britain) : 1987).
[2] J. C. Price,et al. Circulating protein synthesis rates reveal skeletal muscle proteome dynamics. , 2015, The Journal of clinical investigation.
[3] N. Schork,et al. Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study. , 2015, Gastroenterology.
[4] Monjur Ahmed,et al. Non-alcoholic fatty liver disease in 2015. , 2015, World journal of hepatology.
[5] S. Subramaniam,et al. Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study , 2015, Gut.
[6] A. Burt,et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. , 2015, Journal of hepatology.
[7] T. Angel,et al. Turnover Rates of Hepatic Collagen and Circulating Collagen-Associated Proteins in Humans with Chronic Liver Disease , 2015, PloS one.
[8] Zhen Wang,et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[9] D. Brenner,et al. Ezetimibe for the Treatment of Nonalcoholic Steatohepatitis: Assessment by Novel Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Randomized Trial (MOZART Trial) , 2015, Hepatology.
[10] M. Neuman,et al. Biomarkers in nonalcoholic fatty liver disease. , 2014, Canadian journal of gastroenterology & hepatology.
[11] F. Eren,et al. A comparison of FibroMeter™ NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease , 2014, Scandinavian journal of gastroenterology.
[12] Anthony Gamst,et al. Magnetic Resonance Elastography Predicts Advanced Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: A Prospective Study , 2014, Hepatology.
[13] S. Friedman,et al. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? , 2014, Antiviral research.
[14] S. Turner,et al. Proteomic Analysis of Altered Extracellular Matrix Turnover in Bleomycin-induced Pulmonary Fibrosis , 2014, Molecular & Cellular Proteomics.
[15] Rohit Loomba,et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials , 2013, Hepatology.
[16] Richard L Ehman,et al. Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. , 2013, Radiology.
[17] Rohit Loomba,et al. Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes. , 2013, Journal of diabetes and its complications.
[18] R. Ehman,et al. Magnetic resonance elastography of liver: Technique, analysis, and clinical applications , 2013, Journal of magnetic resonance imaging : JMRI.
[19] S. Friedman,et al. Therapy for Fibrotic Diseases: Nearing the Starting Line , 2013, Science Translational Medicine.
[20] G. Gores,et al. Lumican, an extracellular matrix proteoglycan, is a novel requisite for hepatic fibrosis , 2012, Laboratory Investigation.
[21] V. Paradis,et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis , 2012, Hepatology.
[22] D. Brenner,et al. Effect of Colesevelam on Liver Fat Quantified by Magnetic Resonance in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial , 2012, Hepatology.
[23] D. Brenner,et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non‐alcoholic fatty liver disease – MRI accurately quantifies hepatic steatosis in NAFLD , 2012, Alimentary pharmacology & therapeutics.
[24] K. Clément,et al. Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data , 2012, PloS one.
[25] R. Ehman,et al. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. , 2011, Radiology.
[26] D. Schuppan,et al. Tissue transglutaminase does not affect fibrotic matrix stability or regression of liver fibrosis in mice. , 2011, Gastroenterology.
[27] S. Sanderson,et al. Differential expression of lumican and fatty acid binding protein‐1: New insights into the histologic spectrum of nonalcoholic fatty liver disease , 2009, Hepatology.
[28] A. Manduca,et al. Assessment of hepatic fibrosis with magnetic resonance elastography. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[29] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[30] H. Skinner,et al. Alcohol dependence syndrome: measurement and validation. , 1982, Journal of abnormal psychology.
[31] T. Angel,et al. Dynamic Proteomics: In Vivo Proteome-Wide Measurement of Protein Kinetics Using Metabolic Labeling. , 2015, Methods in enzymology.
[32] J. C. Price,et al. Measurement of human plasma proteome dynamics with (2)H(2)O and liquid chromatography tandem mass spectrometry. , 2012, Analytical biochemistry.